NeuroSAFE frozen section during robot-assisted radical prostatectomy (RARP): Peri-operative and Histopathological Outcomes from the NeuroSAFE PROOF Feasibility Randomised Controlled Trial

Objectives: To report on the methods, peri‐operative outcomes and histopathological concordance between frozen and final section from the NeuroSAFE PROOF Feasibility study (NCT03317990). Patients and Methods: Between May 2018 and March 2019 49 men at 2 UK centres underwent robot‐assisted robotic prostatectomy (RARP). 25 men were randomised to NeuroSAFE RARP (intervention arm) vs. 24 men to standard RARP (control arm). Frozen section was compared to final paraffin section margin assessment in the 25 men in the NeuroSAFE arm. Operation timings and complications were collected prospectively in both arms. Results: 50 NVB from 25 patients in the NeuroSAFE arm were analysed. When analysed by each pathological section (n=250, average 5 per side) we note sensitivity 100%, specificity 99.2%, AUC was 0.994 (95% CI 0.985 to 1, P= <.001). On an NVB basis (n=50) we note sensitivity of 100%, specificity 92.7%, and AUC of 0.963 (95% CI 0.914 to 1, p = <0.001. NeuroSAFE RARP lasted a mean 3 hours 16 minutes (knife to skin to off table, 95% CI 3 hrs 2 mins ‐ 3 hrs 30 mins) compared to 2 hours 14 minutes (2 hrs 2 mins ‐ 2 hours 25 mins, P=<0.001) for standard RARP. There was no morbidity associated with the additional length of operation in the NeuroSAFE arm. Conclusion: This feasibility study demonstrates the safety, the reproducibility and the excellent histopathological concordance of the NeuroSAFE technique in the NeuroSAFE PROOF trial. Though the technique increases the duration of RARP, this does not cause short‐term harm. Confirmation of feasibility has led to the opening of the fully powered NeuroSAFE PROOF RCT, which is currently underway at 4 sites in the UK

Comparison of neonatal transient evoked otoacoustic emission responses recorded with linear and QuickScreen protocols

Linear and QuickScreen (non-linear) transient evoked otoacoustic emission (TEOAE) protocols were compared in terms of standardized clinical parameters in order to define the protocol producing recordings with the highest signal quality. Neonatal responses (520) were obtained from three different screening sites. The linear recordings were evoked by 69 and 75-dB p.e. SPL clicks. All responses were post-windowed by a 3.5- to 12.5-ms window, chosen by time-frequency analysis as the segment representing 97.35 per cent (linear) and 95.6 per cent (quick) of the total cumulative spectral energy. Evidence from hearing loss cases and the high similarity between the profile contours of the QuickScreen and the linear normal recordings have strongly suggested that a linear response evoked by a 75-dB p.e. SPL stimulus and post-processed by a 3.5 to 12.5 window is free of stimulus artefacts. The data indicate that the 75-dB linear protocol produces higher signal to noise ratios at 2.0, 3.0, and 4.0 kHz, higher wave reproducibility, and lower TEOAE noise values than the QuickScreen protocol

Assessment of auditory processing in children with dyslalia

The objective of the work was to assess occurrence of central auditory processing disorders in children with dyslalia. Material and method. The material included 30 children at the age 798 years old being under long-term speech therapy care due to articulation disorders. All the children were subjected to the phoniatric and speech examination, including tonal and impedance audiometry, speech therapist&#039;s consultation and psychologist&#039;s consultation. Electrophysi-ological (N2, P2, N2, P2, P300 record) and following psychoacoustic test of central auditory functions were performed (Frequency Pattern Test). Results. Analysis of the results revealed disorders in the process of sound analysis within frequency and P300 wave latency prolongation in children with dyslalia. Conclusions. Auditory processing disorders may be significant in development of correct articulation in children, they also may explain unsatisfactory results of long-term speech therap